EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NQO1/p65/CXCL12 Axis‐Recruited Tregs Mediate Resistance to Anti‐PD‐1 Plus Lenvatinib Therapy in PIVKA‐II‐Positive Hepatocellular Carcinoma

Biao Gao, Yafei Wang, Zhuoya Sun, Haowen Tang, Yinbiao Cao, Hao Jiang, Wenwen Zhang, Yinzhe Xu, Bingyang Hu, Zhe Liu, Guankun Mao, Xuerui Li und 7 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202511152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Biao Gao und 18 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, 100853, China. Hauptthemen laut MEDLINE: Phenylurea Compounds, Quinolines, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) combined with anti‐angiogenic agents manifest improved survival in advanced hepatocellular carcinoma (HCC), but responses remain heterogeneous. Although high PIVKA‐II expression correlates with advanced disease stage, early recurrence, shorter survival, and may predict resistance to anti‐PD‐1 plus lenvatinib therapy, the tumor microenvironment (TME) and resistance mechanisms in HCC with high PIVKA‐II expression remain unclear. Clinical data from 156 resected HCC patients and 104 patients treated with anti‐PD‐1 plus lenvatinib are analyzed to correlate PIVKA‐II expression with clinical features and outcomes. Single‐cell RNA sequencing (scRNA‐seq) is performed on tumors from 15 untreated and 7 treated patients. Mechanistic findings are validated in vitro and in vivo. High PIVKA‐II expression is associated with advanced disease stage, increased microvascular invasion (MVI), early recurrence, and poor response to therapy. ScRNA‐seq revealed an immunosuppressive TME enriched with regulatory T cells (Tregs), exhausted CD8⁺ T cells, and SPP1⁺ tumor‐associated macrophages (TAMs). Mechanistically, tumors with high PIVKA‐II expression upregulated NQO1, which stabilized p65 by inhibiting ubiquitination, activating the NF‐κB/CXCL12 axis, and recruiting Tregs. This pathway mediated therapeutic resistance. Plerixafor, a CXCL12 inhibitor, disrupted this axis and significantly enhanced anti‐tumor efficacy when combined with anti‐PD‐1 plus lenvatinib in vivo. PIVKA‐II is a potentially effective biomarker for predicting resistance to anti‐PD‐1 plus lenvatinib therapy. Its high expression denotes an immunosuppressive TME. Targeting the NQO1/CXCL12/Tregs axis with Plerixafor may restore sensitivity and improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsQuinolinesCarcinoma, HepatocellularLiver NeoplasmsChemokine CXCL12T-Lymphocytes, RegulatoryDrug Resistance, NeoplasmHumansAnimalsMaleFemaleTumor MicroenvironmentMiceImmune Checkpoint InhibitorsMiddle AgedTranscription Factor RelA

Stichwörter der Autor:innen

CXCL12Hepatocellular carcinomaNF‐κBNQO1PIVKA‐IIPlerixaforTregsanti‐PD‐1 plus lenvatinib therapyresistance

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesChemokine CXCL12CXCL12 protein, humanImmune Checkpoint InhibitorsTranscription Factor RelA

Autor:innen und Institutionen

  • Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, 100853, China.
  • Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, 100853, China.
  • Key Laboratory of Digital Hepatobiliary Surgery of Chinese PLA, Beijing, 100853, China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, 471003, China.
  • Medical School of Chinese People's Liberation Army, Beijing, 100853, China.
  • Department of Medical Oncology, Chinese PLA General Hospital, Beijing, 100853, China.

ORCID-Profile: Shichun Lu

Zitieren

APA

Gao, B., Wang, Y., Sun, Z., Tang, H., Cao, Y., Jiang, H., Zhang, W., Xu, Y., Hu, B., Liu, Z., Mao, G., Li, X., Li, J., Wan, T., Liu, B., Zhao, X., Jiao, S., Li, C., & Lu, S. (2025). NQO1/p65/CXCL12 Axis‐Recruited Tregs Mediate Resistance to Anti‐PD‐1 Plus Lenvatinib Therapy in PIVKA‐II‐Positive Hepatocellular Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202511152

Vancouver

Gao B, Wang Y, Sun Z, Tang H, Cao Y, Jiang H, et al. NQO1/p65/CXCL12 Axis‐Recruited Tregs Mediate Resistance to Anti‐PD‐1 Plus Lenvatinib Therapy in PIVKA‐II‐Positive Hepatocellular Carcinoma. Advanced Science. 2025. doi:10.1002/advs.202511152

BibTeX
@article{Gao2025,
  author = {Gao, Biao and Wang, Yafei and Sun, Zhuoya and Tang, Haowen and Cao, Yinbiao and Jiang, Hao and Zhang, Wenwen and Xu, Yinzhe and Hu, Bingyang and Liu, Zhe and Mao, Guankun and Li, Xuerui and Li, Junfeng and Wan, Tao and Liu, Bing and Zhao, Xiao and Jiao, Shunchang and Li, Chonghui and Lu, Shichun},
  title = {NQO1/p65/CXCL12 Axis‐Recruited Tregs Mediate Resistance to Anti‐PD‐1 Plus Lenvatinib Therapy in PIVKA‐II‐Positive Hepatocellular Carcinoma},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202511152}
}
Kostenlos starten →